Allakos Inc (ALLK)
4.625
-0.10
(-2.22%)
USD |
NASDAQ |
Mar 24, 16:00
4.625
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 396.28M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -18.73% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.277 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
03/06 16:02
Yahoo
01/26 05:33
Globe Newswire
11/29 07:02
Globe Newswire
11/10 09:02
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -0.52 | -- | |
| 03/06/2023 | -- | Results | Q4 2022 | -0.50 | -0.57 | 11.76% | |
| 11/07/2022 | -- | Results | Q3 2022 | -0.53 | -0.84 | 36.93% | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.90 | -0.77 | -16.69% | |
| 05/06/2022 | -- | Results | Q1 2022 | -3.60 | -2.44 | -47.67% | |
| 03/01/2022 | -- | Results | Q4 2021 | -1.73 | -1.33 | -29.67% | |
| 11/08/2021 | -- | Results | Q3 2021 | -1.16 | -1.14 | -2.15% | |
| 08/09/2021 | -- | Results | Q2 2021 | -1.07 | -1.07 | 0.13% |
*Estimated Date/Time
Earnings
Profile
Edit
| Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. |
| URL | https://www.allakos.com |
| Investor Relations URL | https://investor.allakos.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Mar. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 322.43M |
| Net Income (TTM) | -319.95M |
| Total Assets (Quarterly) | 386.42M |
| Total Liabilities (Quarterly) | 75.99M |
| Shareholders Equity (Quarterly) | 310.43M |
| Cash from Operations (TTM) | -279.97M |
| Cash from Investing (TTM) | 71.68M |
| Cash from Financing (TTM) | 141.88M |
Ratings
Profile
Edit
| Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. |
| URL | https://www.allakos.com |
| Investor Relations URL | https://investor.allakos.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Mar. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| QCSGX | 6.361M USD | 1.13% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALLK Tweets |